Mara Isabel Lucena Gonzlez

List of Publications by Citations

Source:
https://exaly.com/author-pdf/2196569/maria-isabel-lucena-gonzalez-publications-by-citations.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144 papers	6,772 citations	41 h-index	80 g-index
176 ext. papers	8,147 ext. citations	5.8 avg, IF	5.47 L-index

#	Paper	IF	Citations
144	Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. *Gastroenterology*, **2005**, 129, 512-21	13.3	681
143	Drug-Induced Liver Injury: An Analysis of 461 Incidences Submitted to the Spanish Registry Over a 10-Year Period. *Gastroenterology*, **2005**, 129, 512-521	13.3	554
142	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. *Gastroenterology*, **2011**, 141, 338-47	13.3	359
141	Drug-induced liver injury: Interactions between drug properties and host factors. *Journal of Hepatology*, **2015**, 63, 503-14	13.4	231
140	Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. *Hepatology*, **2006**, 44, 1581-8	11.2	223
139	Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. *Hepatology*, **2009**, 49, 2001-9	11.2	221
138	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. *Hepatology*, **2011**, 54, 931-9	11.2	199
137	Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. *Gastroenterology*, **2014**, 147, 109-118.e5	13.3	186
136	Comparison of two clinical scales for causality assessment in hepatotoxicity. *Hepatology*, **2001**, 33, 123-30	11.2	181
135	Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. *Hepatology*, **2008**, 48, 588-96	11.2	162
134	Drug-induced liver injury. *Nature Reviews Disease Primers*, **2019**, 5, 58	51.1	148
133	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. *Gastroenterology*, **2017**, 152, 1078-1089	13.3	137
132	Causality assessment methods in drug induced liver injury: strengths and weaknesses. *Journal of Hepatology*, **2011**, 55, 683-691	13.4	130
131	Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. *Hepatology*, **2006**, 44, 850-6	11.2	121
130	HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. *Hepatology*, **2004**, 39, 1603-12	11.2	120
129	Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. *Drug Safety*, **2010**, 33, 503-22	5.1	110
128	Deficient Endoplasmic Reticulum-Mitochondrial Phosphatidylserine Transfer Causes Liver Disease. *Cell*, **2019**, 177, 881-895.e17	56.2	109

127	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. *Pharmacogenetics and Genomics*, **2012**, 22, 784-95	1.9	96
126	Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. *Hepatology*, **2010**, 52, 303-12	11.2	85
125	Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. *Journal of Hepatology*, **2016**, 65, 532-42	13.4	82
124	Drug-induced liver injury: insights from genetic studies. *Pharmacogenomics*, **2009**, 10, 1467-87	2.6	80
123	Trovafloxacin-induced acute hepatitis. *Clinical Infectious Diseases*, **2000**, 30, 400-1	11.6	77
122	Effects of silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. *International Journal of Clinical Pharmacology and Therapeutics*, **2002**, 40, 2-8	2	75
121	Mechanisms of drug-induced liver injury. *Current Opinion in Allergy and Clinical Immunology*, **2014**, 14, 286-92	3.3	73
120	Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. *Alimentary Pharmacology and Therapeutics*, **2015**, 41, 116-25	6.1	69
119	Hepatotoxicity induced by herbal and dietary supplements. *Seminars in Liver Disease*, **2014**, 34, 172-93	7.3	69
118	Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. *World Journal of Hepatology*, **2014**, 6, 160-8	3.4	69
117	Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. *Journal of Hepatology*, **2011**, 55, 820-7	13.4	68
116	Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 507-16	18.1	67
115	HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. *PLoS ONE*, **2013**, 8, e68111	3.7	66
114	Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. *Journal of Hepatology*, **2008**, 49, 107-14	13.4	63
113	Antidepressant-induced hepatotoxicity. *Expert Opinion on Drug Safety*, **2003**, 2, 249-62	4.1	63
112	Pharmacogenomics in drug induced liver injury. *Current Drug Metabolism*, **2009**, 10, 956-70	3.5	61
111	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. *Gastroenterology*, **2019**, 156, 1707-1716.e2	13.3	59
110	Causality assessment in drug-induced hepatotoxicity. *Expert Opinion on Drug Safety*, **2004**, 3, 329-44	4.1	59

109	Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. *European Journal of Clinical Pharmacology*, **2002**, 58, 435-40	2.8	58
108	Mitofusin 2 as a driver that controls energy metabolism and insulin signaling. *Antioxidants and Redox Signaling*, **2015**, 22, 1020-31	8.4	57
107	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 1495-1502	6.9	55
106	Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	54
105	The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. *Nature Communications*, **2017**, 8, 2068	17.4	45
104	Biomarkers in DILI: One More Step Forward. *Frontiers in Pharmacology*, **2016**, 7, 267	5.6	43
103	Drug induced liver injury: an update. *Archives of Toxicology*, **2020**, 94, 3381-3407	5.8	40
102	The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative. *International Journal of Molecular Sciences*, **2016**, 17, 313	6.3	40
101	Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure. *Gastroenterology*, **2019**, 157, 552-568	13.3	39
100	Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. *Expert Opinion on Drug Metabolism and Toxicology*, **2011**, 7, 817-28	5.5	38
99	Rechallenge in drug-induced liver injury: the attractive hazard. *Expert Opinion on Drug Safety*, **2009**, 8, 709-14	4.1	38
98	Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). *British Journal of Pharmacology*, **2007**, 150, 808-15	8.6	38
97	Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonist-associated hepatotoxicity. *European Journal of Gastroenterology and Hepatology*, **2002**, 14, 887-90	2.2	36
96	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 245-253	6.1	35
95	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. *Clinical Pharmacology and Therapeutics*, **2019**, 106, 1028-1036	6.1	34
94	Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury. *Liver International*, **2013**, 33, 1378-85	7.9	32
93	The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. *Liver International*, **2015**, 35, 2474-82	7.9	31
92	Continuous reporting of new cases in Spain supports the relationship between Herbalife® products and liver injury. *Pharmacoepidemiology and Drug Safety*, **2011**, 20, 1080-7	2.6	30

91	Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. *Liver International*, **2016**, 36, 302-10	7.9	29
90	Acute liver failure after treatment with nefazodone. *Digestive Diseases and Sciences*, **1999**, 44, 2577-9	4	27
89	Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. *Annals of Hepatology*, **2014**, 13, 231-239	3.1	25
88	Hepatic Damage by Natural Remedies. *Seminars in Liver Disease*, **2018**, 38, 21-40	7.3	24
87	Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. *Liver International*, **2017**, 37, 132-140	7.9	22
86	Drug-induced liver injury: a safety review. *Expert Opinion on Drug Safety*, **2018**, 17, 795-804	4.1	21
85	Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity?. *Journal of Hepatology*, **2015**, 62, 751-2	13.4	21
84	Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. *Current Drug Safety*, **2010**, 5, 212-22	1.4	21
83	Drug use for non-hepatic associated conditions in patients with liver cirrhosis. *European Journal of Clinical Pharmacology*, **2003**, 59, 71-6	2.8	21
82	Genetic and molecular factors in drug-induced liver injury: a review. *Current Drug Safety*, **2007**, 2, 97-112	1.4	20
81	Drug-induced liver injury in older people. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 862-874	18.8	20
80	Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions. *Drug Safety*, **2016**, 39, 925-43	5.1	19
79	Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. *Clinical Therapeutics*, **2009**, 31, 1014-9	3.5	19
78	Chronic liver injury related to use of bentazepam: an unusual instance of benzodiazepine hepatotoxicity. *Digestive Diseases and Sciences*, **2000**, 45, 1400-4	4	19
77	Norfloxacin-induced cholestatic jaundice. *American Journal of Gastroenterology*, **1998**, 93, 2309-11	0.7	19
76	Hepatotoxicity induced by coxibs: how concerned should we be?. *Expert Opinion on Drug Safety*, **2016**, 15, 1463-1475	4.1	18
75	A morphological method for ammonia detection in liver. *PLoS ONE*, **2017**, 12, e0173914	3.7	18
74	Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry. *Journal of Hepatology*, **2021**, 75, 86-97	13.4	18

73	Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity?. *Annals of Pharmacotherapy*, **2004**, 38, 1540-1	2.9	17
72	Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. *Frontiers in Genetics*, **2012**, 3, 273	4.5	16
71	Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report. *World Journal of Gastroenterology*, **2006**, 12, 5244-6	5.6	16
70	Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort. *PLoS ONE*, **2014**, 9, e94675	3.7	15
69	Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles. *Pharmacogenetics and Genomics*, **2016**, 26, 414-22	1.9	15
68	Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice. *Seminars in Liver Disease*, **2019**, 39, 381-394	7.3	14
67	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). *Clinical Liver Disease*, **2019**, 13, 51-57	2.2	14
66	Systematic review: ibuprofen-induced liver injury. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 603-611	6.1	14
65	Idiosyncratic drug hepatotoxicity: a 2008 update. *Expert Review of Clinical Pharmacology*, **2008**, 1, 261-76	3.8	14
64	The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. *European Journal of Gastroenterology and Hepatology*, **2005**, 17, 59-63	2.2	14
63	Chronic hepatitis C, ibuprofen, and liver damage. *American Journal of Gastroenterology*, **2002**, 97, 1854-5	0.7	14
62	"Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge". *Expert Opinion on Drug Metabolism and Toxicology*, **2016**, 12, 589-93	5.5	13
61	Drug-induced autoimmune-like hepatitis: a diagnostic challenge. *Digestive Diseases and Sciences*, **2011**, 56, 2501-2; author reply 2502-3	4	12
60	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1125-1135	6.1	12
59	Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 843-853	6.1	12
58	EASL Clinical Practice Guideline: Occupational liver diseases. *Journal of Hepatology*, **2019**, 71, 1022-1037	13.4	11
57	Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review. *United European Gastroenterology Journal*, **2019**, 7, 825-837	5.3	11
56	Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. *Frontiers in Genetics*, **2012**, 3, 253	4.5	11

55	Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice. *Antioxidants*, **2021**, 10,	7.1	11
54	High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 292-294	6.9	11
53	Differential hepatoprotective role of the cannabinoid CB and CB receptors in paracetamol-induced liver injury. *British Journal of Pharmacology*, **2020**, 177, 3309-3326	8.6	10
52	Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology. *Frontiers in Pharmacology*, **2012**, 3, 2	5.6	10
51	Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]. *Journal of Hepatology*, **2021**, 75, 935-959	13.4	10
50	Acetaminophen-Induced Liver Injury Alters the Acyl Ethanolamine-Based Anti-Inflammatory Signaling System in Liver. *Frontiers in Pharmacology*, **2017**, 8, 705	5.6	9
49	Effect of cyclosporin A on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. *Thrombosis Research*, **1996**, 81, 367-81	8.2	9
48	A Revised Electronic Version of RUCAM for the Diagnosis of Drug Induced Liver Injury.. *Hepatology*, **2022**,	11.2	9
47	Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. *Pharmacological Research*, **2021**, 164, 105404	10.2	9
46	The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury. *Liver International*, **2019**, 39, 401-410	7.9	9
45	Pro-Euro-Dili Registry: A Collaborative Effort to Enhance the Understanding of Dili. *Journal of Hepatology*, **2016**, 64, S293-S294	13.4	8
44	Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach. *Current Pharmaceutical Design*, **2019**, 25, 3855-3871	3.3	8
43	Genetic risk factors in the development of idiosyncratic drug-induced liver injury. *Expert Opinion on Drug Metabolism and Toxicology*, **2021**, 17, 153-169	5.5	8
42	Next-Generation Sequencing of Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. *Frontiers in Genetics*, **2019**, 10, 134	4.5	7
41	Consumo de f□macos relacionados con el tratamiento de la diabetes mellitus y otros factores de riesgo cardiovascular en la poblaci□ espa□ola. Estudio Di@bet.es. *Revista Espanola De Cardiologia*, **2013**, 66, 854-863	1.5	6
40	Syndrome of inappropriate antidiuresis in doxylamine overdose. *BMJ Case Reports*, **2012**, 2012,	0.9	6
39	Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports. *Phytotherapy Research*, **2021**, 35, 6-19	6.7	6
38	Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI. *Journal of Hepatology*, **2021**, 75, 333-341	13.4	6

37	Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. *Annals of Hepatology*, **2014**, 13, 231-9	3.1	6
36	Clinical Characteristics and Outcome of Drug-Induced Liver Injury in the Older Patients: From the Young-Old to the Oldest-Old. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 1147-1158	6.1	5
35	Characterizing Highly Cited Papers in Mass Cytometry through H-Classics. *Biology*, **2021**, 10,	4.9	5
34	DRESS cases included in the Spanish and Latin-American DILI registries: clinical phenotype and outcome. *Journal of Hepatology*, **2018**, 68, S601	13.4	3
33	PP022 Variations in drug-induced liver injury (DILI) between different prospective dili registries. *Clinical Therapeutics*, **2013**, 35, e24	3.5	3
32	518 THE SPANISH LATIN AMERICAN DILI NETWORK: PRELIMINARY RESULTS FROM A COLLABORATIVE STRATEGIC INITIATIVE. *Journal of Hepatology*, **2013**, 58, S212-S213	13.4	3
31	Drug-induced liver and skin reactions: In need of a consensus definition. *Hepatology*, **2017**, 65, 391	11.2	3
30	Reflections on running training workshops for research ethics committee members in Spain between 2001 and 2008. *Croatian Medical Journal*, **2010**, 51, 552-9	1.6	3
29	1137 THE HLA CLASS I B*1801 ALLELE INFLUENCES HEPATOCELLULAR EXPRESSION OF AMOXICILLIN-CLAVULANATE LIVER DAMAGE AND OUTCOME IN SPANISH PATIENTS. *Journal of Hepatology*, **2010**, 52, S439	13.4	3
28	Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.. *Acta Pharmaceutica Sinica B*, **2021**, 11, 3685-3726	15.5	3
27	Statins: Hepatic Disease and Hepatotoxicity Risk **2008**, 2, 18-23		3
26	Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. *Liver International*, **2021**, 41, 1523-1531	7.9	3
25	Serious liver injury induced by Nimesulide: an international collaborative study. *Archives of Toxicology*, **2021**, 95, 1475-1487	5.8	3
24	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	3
23	A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. *American Journal of Gastroenterology*, **2017**, 112, 384-385	0.7	2
22	Indacaterol-induced severe constipation and abdominal pain: is there a role for colonic β-adrenoceptors?. *BMJ Case Reports*, **2013**, 2013,	0.9	2
21	Drug properties and host factors contribute to biochemical presentation of drug-induced liver injury: a prediction model from a machine learning approach. *Archives of Toxicology*, **2021**, 95, 1793-1803	5.8	2
20	Hepatotoxicity in Patients with Metabolic Syndrome: Causes and Consequences. *Current Hepatology Reports*, **2017**, 16, 286-292	1	1

19	The usefulness of TV medical dramas for teaching clinical pharmacology: A content analysis of House, M.D.. *Educacion Medica*, **2019**, 20, 295-303	0.5	1
18	Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. *Genes*, **2020**, 11,	4.2	1
17	Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. *Methods in Pharmacology and Toxicology*, **2018**, 477-496	1.1	1
16	Causality Assessment **2013**, 287-302		1
15	Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions. *Journal of Clinical Medicine*, **2021**, 10,	5.1	1
14	Drug-Induced Liver Disease: Mechanism and Diagnosis **2019**, 715-728		1
13	Lymphocyte Profile and Immune Checkpoint Expression in Drug-Induced Liver Injury: An Immunophenotyping Study. *Clinical Pharmacology and Therapeutics*, **2021**, 110, 1604-1612	6.1	1
12	Methionine Cycle Rewiring by Targeting miR-873-5p Modulates Ammonia Metabolism to Protect the Liver from Acetaminophen. *Antioxidants*, **2022**, 11, 897	7.1	1
11	Use of drugs related to the treatment of diabetes mellitus and other cardiovascular risk factors in the Spanish population. The Di@bet.es study. *Revista Espanola De Cardiologia (English Ed)*, **2013**, 66, 854-63	0.7	0
10	Drug Induced Liver Disease: Mechanisms and Diagnosis **2010**, 771-786		0
9	Reply letter to "Editorial: bodybuilders beware". *Alimentary Pharmacology and Therapeutics*, **2019**, 50, 473	6.1	
8	Reply: To PMID 24704526. *Gastroenterology*, **2015**, 148, 452-3	13.3	
7	Reply: To PMID 24704526. *Gastroenterology*, **2014**, 147, 1442	13.3	
6	Factores de riesgo y mecanismos de toxicidad hep□ica. Da□ hep□ico inducido por medicamentos y t□icos (excluido el alcohol). *Medicine*, **2012**, 11, 573-580	0.1	
5	Un caso de hepatopat□ t□ica. *Medicine*, **2012**, 11, 624.e1-624.e4	0.1	
4	Reply:. *Hepatology*, **2009**, 49, 1777-1779	11.2	
3	Data mining techniques to identify potential clinical presentation modulators in drug-induced liver injury. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO4-9-13	9	
2	Killer Immunoglobulin-Like Receptor Profiles Are not Associated with Risk of Amoxicillin-Clavulanate-Induced Liver Injury in Spanish Patients. *Frontiers in Pharmacology*, **2016**, 7, 280	5.6	

1 Idiosyncratic Drug-Induced Liver Injury: Mechanisms and Susceptibility Factors **2018**, 625-650